I think they're both in the same therapeutic class. What we found was the sales of Lipitor decreased dramatically and the sales of Crestor increased dramatically after Lipitor went off patent, indicating that there was something happening in the marketplace beyond an improvement in the therapeutic applicability of either product.
On October 4th, 2012. See this statement in context.